SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported): January 3, 2006

                           ENZON PHARMACEUTICALS, INC.
             (Exact name of registrant as specified in its charter)


              Delaware                  0-12957          22-2372868
    (State or other jurisdiction      (Commission      (IRS Employer
          of incorporation)          File Number)   Identification No.)


       685 Route 202/206, Bridgewater, New Jersey             08807
        (Address of principal executive offices)           (Zip Code)

        Registrant's telephone number, including area code (908) 541-8600

         (Former name or former address, if changed since last report.)


Check the  appropriate  box below if the Form 8-K is intended to  simultaneously
satisfy  the filing  obligation  of the  registrant  under any of the  following
provisions:

|_|  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

|_|  Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17CFR
     240.14a-12)


|_|  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))


|_|  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))





Item  5.02 (b)  Departure  of  Directors  or  Principal  Officers;  Election  of
Directors; Appointment of Principal Officers.

By  letter  dated  January  3,  2006,  Rosina  Dixon,  a member  of the Board of
Directors  advised the Company that she would retire from the Board of Directors
effective April 30, 2006.



                                        2







                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Dated: January 9, 2005

                                 By:  /s/ CRAIG A. TOOMAN
                                 Name:  Craig A. Tooman
                                 Title:  Executive Vice President, Finance
                                 and Chief Financial Officer